From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Adverse event | All grades N (%) | Grade ≥ 3 N (%) |
---|---|---|
Fatigue | 3 (19) | |
Rash, maculo-papulara | 2 (13)a | |
Hypothyroidisma | 2 (13)a | |
Anorexia | 2 (13) | |
Colitisa | 1 (6)a | 1 (6)a |
Pneumonitisa | 1 (6)a | 1 (6)a |
Dyspneaa | 1 (6)a | |
Arthralgiaa | 1 (6)a | |
Myalgiaa | 1 (6)a | |
Nausea | 1 (6) | |
Mucositis oral | 1 (6) | |
Dry skin | 1 (6) | |
Anemia | 1 (6) | |
Alanine aminotransferase increased | 1 (6) | |
Aspartate aminotransferase increased | 1 (6) |